Jabar A Faraj

Title: Jabar A Faraj: Innovator in Fulvestrant Formulations

Introduction

Jabar A Faraj is a notable inventor based in Birmingham, AL (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of fulvestrant formulations. With a total of four patents to his name, Faraj's work focuses on innovative solutions for treating hormone receptor positive metastatic breast cancer.

Latest Patents

Faraj's latest patents include two formulations of fulvestrant. The first patent describes a fulvestrant composition that comprises a pharmaceutically acceptable vehicle with no more than 2% total impurities. This formulation is designed to be free of a non-aqueous ester solvent and is intended for the treatment of hormone receptor positive metastatic breast cancer in patients. The second patent also focuses on fulvestrant formulations, emphasizing a composition that includes a nonionic surfactant and/or a ricinoleate vehicle, again ensuring that total impurities do not exceed 2%. This formulation, too, is aimed at treating hormone receptor positive metastatic breast cancer.

Career Highlights

Jabar A Faraj is currently associated with Fresenius Kabi USA, LLC, where he continues to innovate in the pharmaceutical sector. His work is characterized by a commitment to improving treatment options for patients suffering from serious health conditions.

Collaborations

Due to space constraints, the collaborations section will be omitted.

Conclusion

Jabar A Faraj is a prominent inventor whose work in fulvestrant formulations has the potential to significantly impact the treatment of hormone receptor positive metastatic breast cancer. His contributions to the field exemplify the importance of innovation in healthcare.